Harpoon rises on positive study data for cancer therapy

Harpoon Therapeutics

23/10/2023 12:46

** Shares of therapy developer Harpoon Therapeutics  HARP.O 
rise ~12.2% to $7.74 premarket
    ** Co said on Friday that its experimental therapy HPN328
showed a response rate of 32% in patients with small cell lung
cancer
    ** The therapy also showed a response rate of 35% across all
tumor types in one patient cohort and a response rate of 42% in
a patient group with cancers such as prostate cancer, small cell
bladder cancer, and large cell lung cancer 
    ** Response rate is defined as the proportion of patients
who have a partial or complete response to therapy
    ** Up to last close, shares down 5.2% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))